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Abstract 
Objectives: The optimal timing of subthalamic nucleus (STN) deep brain stimulation 
(DBS) in Parkinson’s disease (PD) is a topic of ongoing debate. In patients with short 
disease duration an improvement of quality of life (QoL) has been demonstrated for 
patients aged younger than 61 years. However, this has not been systematically 
investigated in older patients yet. 
Material and Methods: From four centers (Cologne, London, Manchester, Venice) 
we identified ‘older patients’ aged 61 years or older with short (≤8 years) or longer 
disease duration and compared quality of life (QoL), motor impairment, 
complications, medication requirements, and MMSE on baseline and 5 months after 
surgery. 
Results: Mean age/disease duration in 21 subjects with shorter disease duration 
were 65.5/6.3 years compared to 66.8/14.6 in 33 subjects with longer disease 
duration. The short disease duration group was affected by less baseline motor 
complications (p=0.002). QoL in the short/longer disease duration group improved by 
35/20% (p=0.010/p=0.006), motor complications by 40/44% (p=0.018/p<0.001) and 
medication requirements by 51/49% (both p<0.001). MMSE remained unchanged in 
both groups. 
Conclusion: Patients aged 61 years or older benefited from STN-DBS regardless of 
short (≤8 years) or longer (>8 years) disease duration. Our results contribute to the 
debate about DBS selection criteria and timing and call for prospective confirmation 
in a larger cohort. 
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1. Introduction 
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a well-established 
treatment option for patients with Parkinson’s disease (PD) improving motor 
symptoms1 and quality of life (QoL)2-5. In recent years, the expansion of the 
traditional indication for DBS by intervention at earlier stages of PD has emerged as 
a major topic of debate6-8. 
In the EARLYSTIM study, a randomized, controlled trial with relatively young patients 
(mean age 52.9 years) with short disease duration (mean 7.3 years) and short 
duration of motor complications (≤3 years), STN-DBS was superior to best medical 
treatment regarding quality of life (QoL), motor function and medication 
requirements6. An inclusion criterion in this study was age <61 years. However, ‘older 
patients’, aged 61 years or older, form a majority of the PD population9. Previous 
studies have not provided evidence for an improvement of quality of life in older 
patients with PD undergoing bilateral STN-DBS10 and the effects of subthalamic 
neurostimulation in the subpopulation of older patients with short duration of PD 
remain to be investigated. 
In spite of their possible suitability, neurostimulation might not be considered for 
these patients due to a rather high degree of uncertainty regarding its benefits and 
complications. We thus analyzed baseline characteristics and outcome parameters of 
this subpopulation of patients aged 61 years or older with short disease duration (≤8 
years) and compared results to patients with the same age and longer disease 
durations of PD (>8 years). We hypothesized that patients aged 61 years or older 
experience a significant QoL improvement after STN-DBS with no difference in effect 
sizes for groups of patients with short and longer disease duration. 
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2. Methods 
2.1. Study Design 
For this post-hoc analysis of prospective data collected between August 2011 and 
January 2015, we screened the databases in four European DBS centers (Cologne, 
London, Manchester, Venice; IPMDS Non-Motor PD Study Group – DBS Section) for 
patients aged ≥61 years at surgery who underwent bilateral STN-DBS due to motor 
complications or medication refractory PD tremor. 
To categorize our cohort of older patients aged ≥61 years into two groups, one with 
short and another with longer disease duration, we chose 8 years or less at surgical 
intervention as a cut-off for disease duration based on the mean baseline disease 
duration of the neurostimulation group in the EARLYSTIM trial which was 7.3 (±3.1) 
years6. A cut-off based on disease duration was chosen as the onset and duration of 
motor fluctuations had not been systematically recorded in our database. 
 
2.2. Patients and surgical procedures 
PD diagnoses were based on UK Brain Bank criteria11 and eligibility for bilateral STN-
DBS had been verified at each center by an experienced multidisciplinary team. This 
involved exclusion of clinically relevant psychopathology or neuropsychological 
deficits, confirmation of levodopa responsiveness and exclusion of surgical 
contraindications. 
All patients underwent bilateral subthalamic lead implantation in a single session. 
The STN was targeted visually by stereotactic MRI, assisted by intraoperative 
electrophysiological mapping according to established procedures at each center. 
Final lead positions were determined clinically and confirmed by postoperative 
imaging. The subcutaneous impulse generator was implanted either in the same 
session or shortly thereafter. Stimulation and adjustment of medication was 
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commenced within few days after completion of surgical procedures at the discretion 
of the movement disorder specialists in each center. 
 
2.3. Clinical assessments 
The main outcome of this analysis was QoL change from preoperative baseline to 
postoperative follow-up rated with the Parkinson’s Disease Questionnaire-8 (PDQ-8) 
which has previously been used for patients with PD and STN-DBS12, 13. The PDQ 
has been recommended by the ad hoc Task Force of the Movement Disorders 
Society as an instrument to assess quality of life in patents with PD14 and previously 
been used as a primary endpoint in various large DBS trials2, 5, 6. Domains of the 
PDQ comprise mobility, activities of daily living, emotional well-being, stigma, social 
support, cognition, communication and bodily discomfort with higher scores indicating 
lower quality of life. All results are reported as PDQ-8 summary index (PDQ-8 SI)15. 
Motor impairment was assessed preoperatively in levodopa challenge tests as per 
clinical routine and documented with the Unified Parkinson’s Disease Rating Scale-III 
(UPDRS-III) and its revised version (MDS-UPDRS part 3; 47 and 7 patients, 
respectively)16.  
Postoperative motor impairment was assessed with heterogeneous instruments in 
patients in clinical ON states with neurostimulation plus medication 
(MedON/StimON). Of the 54 patients, the MDS-UPDRS was available for 7 patients 
and the UPDRS for 31 patients. In the remaining 16 patients, motor impairment was 
assessed with the Short Parkinson’s Evaluation Scale/Scales for Outcomes in 
Parkinson’s disease (SPES/SCOPA) which was deducted from the UPDRS and 
strongly correlates with it17, 18. The overall clinimetric properties of the SPES/SCOPA 
and UPDRS, including their inter- and intra-rater reliability, are good and the 
construct validity of the SPES/SCOPA referenced to the UPDRS is also good based 
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on correlations between corresponding components of the two scales, such as motor 
impairment17. Based on previously published conversion methods19, 20, here we 
report motor impairment ratings as MDS-UPDRS part 3 scores to enable 
comparisons across patients and simplify the interpretation of data. 
For motor complications, the heterogeneous rating instruments were harmonized by 
comparing percentages of their maximum scores as there is no validated conversion 
method of SCOPA-motor complications to the (MDS)-UPDRS motor complications 
section. 
Accordingly, tremor items of available scales were summarized as percentages of 
their maximum score to provide “tremor sub-scores” (UPDRS part III items 20 and 
21, MDS-UPDRS part 3 items 3.15–3.18, and SPES/SCOPA motor examination, 
items 1 and 2). 
Furthermore, we calculated the levodopa equivalent daily dose (LEDD) according to 
the formulae previously published by Tomlinson et al.21. 
All patients underwent neuropsychological assessment as routine for their centers, 
using various tests which differed amongst centers. For a general cognitive measure, 
we only present the Mini-Mental State Examination (MMSE) results as this was found 
to be a common factor amongst the operating centers in this study. 
 
2.4. Adverse events 
Adverse events (AE) were extracted from databases/patient files and codified 
according to the following criteria: any event leading to death, disability or prolonged 
or new hospitalization with serious health impairment was considered serious AE 
(SAE). As an exception, scheduled hospitalizations for DBS follow-up were not 
considered serious. Mild, moderate or severe AE were categorized according to their 
extent of interference with normal function and their consequences, with moderate 
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AE possibly interfering with normal activity and leading to the consideration of 
medical intervention or close follow-up and severe AE posing a substantial risk to the 
patient’s health and requiring medical intervention or close follow-up. 
 
2.5. Statistical analysis 
After analyzing the normality of distribution with Shapiro-Wilk tests, baseline features 
of the short and longer disease duration groups were compared using the Mann-
Whitney U test. The relationship between disease duration and preoperative motor 
impairment (OFF) was explored using Spearman correlation analysis. Additionally, to 
confirm this analysis, a median split of preoperative motor impairment was used to 
compare disease duration in patients with high and low motor impairment. In the 
main statistical analysis, we analyzed QoL changes intra-group from baseline to 
follow-up employing the Wilcoxon signed-rank test with Bonferroni-correction for the 
two comparisons. Additionally, we explored changes of motor impairment, motor 
complications, LEDD, and MMSE at follow-up as secondary outcomes. In order to 
better illustrate the magnitude of change at follow-up, Cohen’s effect size was 
calculated for each outcome and categorized into “small” (effect size: 0.20 –0.49), 
“moderate” (effect size: 0.50 – 0.79) and “large” (effect size: ≥0.80)22. 
 
3. Results 
3.1. Baseline 
From our databases we identified 54 consecutive patients fulfilling the age inclusion 
criterion (≥61 years): 21 patients in the short disease duration group with a mean age 
and disease duration of 65.5 (±6.3) and 6.3 (±1.2) years and 33 patients in the longer 
disease duration group with 66.8 (±3.2) and 14.6 (±6.7) years. 
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Baseline assessment was carried out shortly before surgery (mean: 6.2 ±9.4 days, 
95% confidence interval [CI]=3.4–9.0). Baseline motor complications (p=0.002) were 
significantly higher in the longer disease duration group. Other characteristics did not 
differ significantly, although values for motor impairment and tremor sub-scores were 
higher in the short disease duration group. In our cohort, no significant relationship 
was found for disease duration and motor impairment in Spearman correlation and 
median split analyses. 
Baseline characteristics are presented in the Table 1, age distribution in Figure 1. 
 
3.2. Follow-up 
Follow-up assessments were carried out approximately 5 months after surgery 
(mean: 156 days ±41.7, CI=143.3–167.8). QoL significantly improved in both groups 
(short disease duration group: p=0.010; longer disease duration group: p=0.006; see 
Table 2 and Figure 2). As expected, motor impairment significantly improved in the 
comparison of preoperative MedOFF to postoperative MedON/StimON (short 
disease duration group: p<0.001; longer disease duration group: p<0.001) while no 
significant change was found between preoperative MedON and postoperative 
MedON/StimON (both p>0.05). 
Furthermore, while MMSE did not change significantly in either group, other 
exploratory outcomes, such as LEDD and motor complications, significantly improved 
in both groups (see Table 2). 
Effect sizes were ‘moderate’ for QoL and ‘large’ for LEDD reduction and motor 
examination (comparing preoperative MedOFF and postoperative MedON/StimON) 
in both groups. For motor complications, they were ‘small’ in the short disease 
duration, but ‘large’ in the longer disease duration group. 
In both groups, tremor was significantly reduced with a relative change of about 50%. 
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3.3. Adverse events 
AE and serious AE (SAE) are listed in detail in Table 3. SAE frequency was 
comparable in both groups (2 SAE/9.5% in the short, 4 SAE/12.1% in the longer 
disease duration group). The occurrence of AE per age group is shown in Table 4. 
No statistically significant difference in the frequency of AE could be observed with 
regard to age although the small number of patients older than 71 years potentially 
distorts the analysis. 
In the short disease duration group, in one patient surgical revision of the implantable 
pulse generator became necessary due to impaired wound healing. This occurred in 
two patients of the longer disease duration group. One patient in the longer disease 
duration group suffered from severe and prolonged postoperative confusion which 
led to psychiatric hospitalization and intensified neuroleptic treatment. One patient in 
the short disease duration group experienced a transient delirious state. Delirium 
occurred after activation of ventral contacts, required temporary treatment in an 
intensive care unit and resolved completely after reprogramming and adjustment of 
medication. The removal of a suprapubic catheter and surgery for adenoma of the 
prostate in one patient in the longer disease duration group ere unrelated to PD. 
For non-serious AE the general distribution and profile did not differ between the 
groups with the exception of falls and dyskinesia which occurred more frequently in 
the longer disease duration group. In around 10% of patients in both groups gait 
disorders were observed. 
 
4. Discussion 
Bilateral STN-DBS in patients aged ≥61 years improved QoL and motor symptoms, 
irrespective of short (≤8 years) or longer (>8 years) disease duration of PD. These 
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findings resemble studies of younger patients with neurostimulation after short 
disease duration6 and of older patients matching the traditional selection profile in 
terms of a longer disease duration1, 2, 5.  
 
4.1. Baseline characteristics and DBS outcomes 
Considering the minimally important difference for the PDQ-8 SI (5.8 – 7.4 points)23, 
patients in both groups experienced relevant QoL improvement. Effect sizes for QoL 
were ‘moderate’ and for motor impairment ‘large’, supporting a robust and meaningful 
change. Few studies have investigated QoL outcomes stratified by age and disease 
duration. Derost et al. analyzed QoL outcomes in two age groups with a cut-off at 65 
years10 and reported negative results in the older compared to the younger group for 
specific PDQ domains (‘Stigma’, ‘Cognition’, ‘Communication’, ‘ADL’, and ‘Mobility’). 
However, the authors did not provide information whether absolute changes of PDQ 
total and domain scores changed significantly after surgery in each group. Other 
studies assessing age-dependent QoL outcomes after STN-DBS only reported 
negative results for correlation analyses between QoL outcome and age at 
intervention and also did not report the absolute QoL changes for different age 
groups including patients aged 61 years or older24, 25. As regards disease duration 
and QoL outcome, previous studies including patients with limited disease duration 
(<10 years)26 and at early disease stages6 included relatively young patients aged 
<55, respectively <61 years. Therefore, as age may be a crucial confounding factor, 
the comparability of our results with these studies seems very limited. 
 
The greater extent of baseline motor complications in the longer disease duration 
group was to be expected as a result of later disease stage and the marked 
postoperative improvement resulted in a ‘large’ effect size. In contrast, although a 
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significant improvement was also observed in the short disease duration group, its 
effect size was only ‘small’. 
The analysis of tremor sub-scores showed a significant improvement of about 50% in 
both groups (see Table 2). Interestingly, baseline tremor scores were about twice as 
high in the short disease duration group. Thus, the impact of tremor reduction was 
particularly meaningful for these patients and supports the indication for DBS 
treatment in this group despite lower scores for motor complications. 
In our cohort, the frequency of AE, especially of surgical complications, did not 
exceed the rates commonly reported27. 
 
4.2. Age and disease duration 
Both the application of STN-DBS at short disease duration stages of PD and in older 
patients are topics of vivid debate6, 7, 28-30. 
The concept of early neurostimulation has been criticized due to medical, 
socioeconomic and scientific concerns28 and many patients are cautious about 
undergoing early DBS29. On the other hand, the authors of the EARLYSTIM study 
proposed their strategy as a possibility to prevent social, occupational and 
professional withdrawal and prolong the phase of good QoL at a critical point in the 
disease course6, 7, 30. 
Age has repeatedly been implied as a negative predictor for DBS outcomes, e.g. 
surgical complications31, motor functions32, QoL and axial signs10, 33. However, 
recently its role as a rigid exclusion criterion was questioned when similar 
complication rates were reported between elderly (>75 years) and younger patients31 
although this study focused on all targets, not just STN. Randomized, controlled trials 
report no influence of age on motor improvement as a statistically independent factor 
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in STN-DBS34. Surgical complications seem to depend mainly on comorbidities, for 
which age serves as a surrogate35.  
Consequently, in our cohort of older patients the perioperative risk may rise with 
increasing comorbidities at higher age and particularly in patients aged between 60 
to 70 years more years of disease duration until DBS could result in a loss of years 
with good QoL.  
 
4.3. Looking beyond age and disease duration – the need for better 
surrogates 
Higher age and longer disease duration at surgery are associated with more non-
dopaminergic motor phenomena36. Postoperatively, with progressing disease these 
symptoms gradually limit DBS efficacy1, 37.  
Generally, the response to medical and surgical treatment seems to depend on the 
interplay of age, disease duration and clinical phenotype. This also becomes 
apparent in our cohort: Despite a significantly longer disease duration in the 
corresponding group, motor impairment and QoL at baseline were comparable in 
both groups, seemingly suggesting a faster progression of parkinsonian symptoms in 
the short disease duration group. However, in our cohort, we did not find a significant 
relationship between disease duration and motor impairment in correlation and 
median split analysis. Instead, this apparent mismatch might in part result from the 
relatively higher, albeit statistically not significant, tremor sub-scores in the short 
disease duration group. This higher tremor sub-score might also explain the fact that 
higher motor impairment and yet less motor complications were observed in this 
group. These findings point to tremor as an important phenotypic characteristic in the 
evaluation of surgical candidacy in older patients with short disease duration. 
Page 13 of 31
Neuromodulation Proof
Neuromodulation Proof
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Running title: “STN-DBS in age ≥61 years with short PD duration”  
Age and disease duration rather seem to serve as surrogates for factors detrimental 
to DBS outcomes, such as comorbidities, axial signs and cognitive impairment. 
Except for comorbidities, which correlate mainly with age35, their development might 
be more reliably associated with the individual disease characteristics. Subtypes of 
PD could offer better outcome predictions than mere demographic features such as 
chronological age. 
 
4.4. Limitations 
Our results need to be interpreted with caution due to a number of limitations. 
Despite the involvement of four DBS centers, the size of our short disease duration 
group was rather small. This in turn may indicate the clinical underrepresentation of 
older patients with DBS and short disease duration of PD. The relative 
underrepresentation of women in the short disease group is in line with previous 
studies which have reported that men seem to be undergoing DBS earlier than 
women38 which may be based on patients’ wishes, position in society39 and an 
underrepresentation in referrals for DBS surgery40. The high variability of clinical data 
is likely explained by the small sample size, especially in the short disease duration 
group which as discussed may be more prone to a higher degree of clinical 
heterogeneity in stages of shorter disease duration. Further studies including more 
patients are needed to investigate this issue. 
The cognitive assessment is limited as the MMSE is not a disease specific 
instrument and therefore has limited utility in PD.  
Although the concept of our study investigating DBS outcomes such as QoL, motor 
functions, medication requirements in older patients with short disease duration, 
somehow echoes the concept of the EARLYSTIM study, it is important emphasize 
basic methodological differences: Above all, the EARLYSTIM study was a large, 
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randomized and controlled prospective trial. In the EARLYSTIM study, a main 
inclusion criterion was ≤3 years duration of motor fluctuations to enable inclusion of 
patients at early stages of disease progression. As the duration of motor fluctuations 
had not been systematically recorded in our databases, we cannot confirm disease 
progression stages based on the same designated cut-off as in the EARLYSTIM 
study. However, a short disease duration based on a 8 year cut-off seemed to be a 
sensible approach to approximate this criterion as motor complications do not occur 
in >90% for dyskinesia and >85% for motor fluctuations during the first five years of 
the disease41. 
The lack of a best medical treatment group, the unblinded clinical assessments, and 
the inclusion criteria based on disease duration instead of duration of motor 
complications and the retrospective character highly limit the comparability of our 
study with EARLYSTIM. Furthermore, due to the shorter observation period in our 
study, e.g., AE counts cannot be directly compared between the studies. 
Due to the design of our database as a prospective, but non-interventional 
longitudinal observation, only clinical ON states (MedON/StimON) were recorded at 
the follow-up assessments. MedOFF/StimON values were thus not available, limiting 
the analysis of the pure stimulation effects on QoL and motor outcomes. The LEDD 
reduction and the comparison of postoperative MedON/StimON to the preoperative 
MedOFF and MedON scores observed in our cohort were, however, well within the 
range of previous studies1, 2, 5, 6. 
A longer follow-up will need to address the long-term outcome, especially the 
development of non-dopaminergic, non-motor, and axial symptoms. From our 
relatively short follow-up, we cannot predict the durability of QoL improvements. 
Although the alleviation of especially appendicular motor symptoms by STN-DBS is 
known to be quite sustainable, comorbidities and the factors mentioned above may 
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reduce the differences between surgical management at different disease stages and 
medical treatment in an older cohort. 
To conclude, our study provides preliminary evidence for a potential benefit of 
subthalamic neurostimulation after short disease duration in an older PD 
subpopulation. 
However, this group of older patients with short disease duration might rather 
epitomize the impact of individual disease type and health status than that of 
demographic features on DBS outcomes. This emphasizes the need to look beyond 
demographical features in determining surgical candidacy. 
Although due to its exploratory character no general recommendations can be 
derived from our study, it adds another piece to the puzzle of patient selection for 
neurostimulation. 
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Table 1 – Baseline characteristics 
  
Short disease duration  
(n = 21) 
    
Longer disease duration 
(n = 33) 
  p
ǂ
   
Sex (male/female) 17/4 (81/19%) 
    
18/15 (54.5/45.5%) 
      
Age at intervention (years 
±SD, range) 
65.5 (±6.3) 
    
66.8 (±3.2) 
  
n.s. 
Disease duration at surgery 
(years) 
6.3 (±1.2) 
    
14.6 (±6.7) 
  
< 0.001
τ
 
PDQ-8 Summary Index 34.8 (±20.7) 
    
32.2 (±10.9) 
  
n.s. 
 
Motor impairment  
(MDS-UPDRS part 3) 
Med OFF 
46.4 (±16.8) 
    
44.4 (±14.65) 
  
n.s. 
 
Med ON 25.1  (±11.5)   24.6 (±10.49)  n.s.  
Tremor 
(% of maximum tremor 
score) 
22.9  (±23.7) 
  
10.1  (±10.8) 
 
n.s. 
 
Motor complications 
(% of maximum score) 
28.3 (±27.6) 
    
49.3 (±20.0) 
  
0.002* 
 
LEDD (mg) 1029.0 (±607.6) 
    
1212.5 (±470.6) 
  
n.s. 
 
MMSE 29.2 (±0.9)     28.6 (±1.4)   n.s.  
                  
  
Abbreviations: LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorders Society – Unified 
Parkinson’s Disease Rating Scale; MMSE = Mimimal Mental State Examination; PDQ-8 SI = 8-item Parkinson’s 
Disease Questionnaire Summary Index 
 
‡ Mann-Whitney U test  
τ Significantly shorter disease duration of Parkinson’s disease in corresponding group  
* Significantly less motor complications in the short disease duration group 
n.s.: not significant (p > 0.05) 
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Table 2 – Outcome parameters at follow-up and comparison with baseline 
  
Short disease duration (n = 21) Longer disease duration (n = 33) 
  
Baseline Follow-up ∆ 
Relative 
change (%) 
p  
Effect 
size 
τ
 
Baseline Follow-up ∆ 
Relative 
change (%) 
p  
Effect 
size 
τ
 
PDQ-8 Summary Index 34.8 (±20.7) 22.5 (±15.7)
 
  - 12.3 -35.3 0.010 Ƣ 0.59 32.2 (±10.9) 25.9 (±11.1) - 6.3 - 19.6 0.006 Ƣ 0.58 
Motor impairment  
(MDS-UPDRS part 3) 
MedOFF:  
46.4 (±16.8)  
25.0 (±13.9) 
21.4 -46.1 <0.001 1.27 
MedOFF: 
44.4 (±14.7) 
28.8 (±7.9) ơ 
15.6 -35.2 <0.001 1.06 
MedON:  
25.1 (±11.5) 
0.1 -0.4 n.s. 0.00 
MedON: 
24.6 (±10.5) 
- 4.2 17.0 n.s. 0.40 
Tremor Scores  
(% of maximum 
tremor score) 
22.9 (±23.7) 10.4 (±15.4) - 12.5 - 54.6 0.004 0.53 10.1 (±10.8) 5.2 (±6.8) - 4.9 - 48.5 0.037 0.45 
Motor complications  
(% of maximum score) 
28.3 (±27.6) 17.1 (±21.5)
 Φ
 - 11.2 -39.6 0.018 0.41 49.3 (±20.0) 27.5 (±23.3) ơ - 21.8 -44.2 < 0.001 1.09 
LEDD (mg) 1029.0 (±607.6) 500.4 (±302.9) - 528.6 -51.4 < 0.001 0.87 1212.5 (±470.6) 623.3 (±300.4) - 589.2 -48.6 < 0.001 1.25 
MMSE 29.2 (±0.9) 29.2 (±1.2)
 Φ
 0 0 n.s. 0 28.6 (±1.4) 28.7 (±1.6) 0.1 0.3 n.s. 0.07 
                          
  
Abbreviations: LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorders Society – Unified Parkinson’s Disease Rating Scale; MMSE = Mimimal Mental State 
Examination; PDQ-8 Summary Index = 8-item Parkinson’s Disease Questionnaire Summary Index 
 
Scores for motor complications are presented as percentage of maximum scores to allow comparison across different rating scales. Maximum score for motor complications is 20 points in 
the UPDRS part IV (maximum score of the entire part IV is 23, but items 40-42 with a maximum score of 3 relate to non-motor symptoms and were excluded), 24 points in the MDS-UPDRS 
part 4 and 12 points  in the SPES/SCOPA part C. 
∆ Absolute change (Baseline – Follow-up) 
Ƣ Wilcoxon signed-rank test with Bonferroni-correction for Type I error of main outcome (PDQ-8 Summary Index) 
τ Effect sizes: "small" (0.20-0.49), "moderate" (0.5-0.79) and "large" (>0.80) 
Φ Follow-up motor complications score and MMSE each missing in one patient of the shorter disease duration group (n = 20) 
ơ Follow-up motor impairment and motor complications score each missing in one patient of longer disease duration group (n = 32) 
n.s.: not significant (p > 0.05) 
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Table 3 - Adverse Events             
              
Event Short disease duration (n = 21) Longer disease duration (n = 33) 
              
  
No. of events No. of patients with 
event (%) 
No. of events No. of patients with 
event (%) 
              
Serious adverse events 2 2 (9.5) 4 4 (12.1) 
Death 0 0   0 0   
Life-threatening event 0 0   0 0   
Event related to medication 0 0   0 0   
Event related to surgery or device 1 1 (4.8) 3 3 (9.1) 
Postoperative confusion 0 0   1 1 (3.0) 
Impaired wound healing
¶
 1 1 (4.8) 2 2 (6.1) 
Event related to stimulation 1 1 (4.8) 0 0   
Transient delirious state
Φ
 1 1 (4.8) 0 0   
Event related to Parkinson's disease 0 0   0 0   
Other
ǂ
 0 0   1 1 (3.0) 
              
              
Adverse events             
Mild 14 11 (52.4) 23 16 (48.5) 
Moderate 15 9 (42.9) 24 16 (48.5) 
Severe 1 1 (4.8) 9 8 (24.2) 
              
Moderate or severe             
Dyskinesia 1 1   7 6   
Gait disorder 2 2   3 3   
Worsening of mobility 0 0   1 1   
Depression 0 0   0 0   
Impulse control disorder 0 0   1 1   
Pain 1 1   2 2   
Hypersalivation 1 1   0 0   
Falls 1 1   4 4   
Motor fluctuations 1 1   1 1   
Anxiety 0 0   2 2   
Hypomania 0 0   1 1   
Dopamine withdrawal syndrome 1 1   2 2   
REM behaviour disorder 1 1   1 1   
Cognitive disturbance 0 0   1 1   
Daytime sleepiness 1 1   0 0   
Dysarthria 1 1   2 2   
Subcutaneous seroma/hematoma 1 1   0 0   
Postoperative confusion 1 1   2 2   
Disturbed wound healing 1 1   1 1   
Paraesthesias due to device 0 0   0 0   
Gastrointestinal disorder 1 1   0 0   
Infections (excl. device related) 1 1   1 1   
Sexual function/fertility disorders 0 0   1 1   
Other 0 0   0 0   
              
 
¶ Impaired wound healing around the implantable pulse generator in these patients required surgical revision 
ǂ The removal of a suprapubic catheter and surgery for adenoma of the prostate in one patient were unrelated to PD 
Φ Disorientation, confusion and mania after activation of contact 0 required transient sedation and surveillance on Intensive Care Unit, 
resolved completely after adjustment of medication and stimulation 
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Table 4 - Adverse events per age group 
Age group No. of patients No. of events (%) 
    Total Mild Moderate Severe Serious 
61 - 65 26 38 13 (34.2) 17 (44.7) 5 (13.2) 3 (7.9) 
66 - 70 22 39 17 (43.6) 15 (38.5) 5 (12.8) 2 (0.1) 
71 - 75 6 15 7 (46.7) 7 (46.7) 0 (0) 1 (6.7) 
Sum 54 92 37 (40.2) 39 (42.4) 10 (10.9) 6 (6.5) 
 
Table 4 lists all adverse events per age group. Percentages refer to the total of each age 
group and the sum of all events respectively. 
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Figure 1 – Distribution of patients according to age group and disease duration 
at surgery 
 
 
 
Figure 1 shows that age in both the short disease duration group (red) and the 
longer disease duration group (grey) ranged from 61 to 75 years. The majority 
of patients in our cohort were between 61 to 70 years of age at surgery. 
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Figure 2 – Box and line plots of quality of life in patients aged 61 years or older 
with short and longer disease duration 
 
 
 
Figure 2 illustrates a significant improvement of quality of life in patients aged 
≥61 years with short (≤8 years, 2a) and longer disease duration (>8 years, 2b) at 
deep brain stimulation surgery.  
Big black stars and p-values indicate significant changes. Outliers are indicated 
with small circles (between 2 to 3 SD). 
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